160 Health International (HKSE:02656) EBIT: HK$-78.3 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02656 160 Health International Ltd HKSE:02656
8 GF Score
Price HK$9.64
! 5 Warning Signs
View Full Analysis

What is 160 Health International EBIT?

160 Health International HKSE:02656 -2.87% 8 EBIT is HK$-78.3 Mil as of Dec. 2025. GuruFocus rates HKSE:02656 with a GF Score™ of 8/100. The stock has 5 warning signs investors should review.

160 Health International's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was HK$-60.4 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-78.3 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. 160 Health International's annualized ROC % for the quarter that ended in Dec. 2025 was -36.20%. 160 Health International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -290.03%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. 160 Health International's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -2.40%.

160 Health International  (HKSE:02656) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

160 Health International's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-109.33 * ( 1 - 5.56% )/( (202.227 + 368.254)/ 2 )
=-103.251252/285.2405
=-36.20 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=332.448 - 247.277 - ( 72.99 - max(0, 432.006 - 314.95+72.99))
=202.227

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=839.51 - 240.526 - ( 440.571 - max(0, 570.84 - 801.57+440.571))
=368.254

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

160 Health International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-120.814/( ( (13.563 + max(-75.726, 0)) + (13.376 + max(56.372, 0)) )/ 2 )
=-120.814/( ( 13.563 + 69.748 )/ 2 )
=-120.814/41.6555
=-290.03 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(185.985 + 1.626 + 43.733) - (247.277 + 0 + 59.793)
=-75.726

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(225.239 + 22.156 + 110.904) - (240.526 + 0 + 61.401)
=56.372

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

160 Health International's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-78.343/3265.880
=-2.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

160 Health International EBIT Related Terms

160 Health International EBIT Historical Data

* Premium members only.

The historical data trend for 160 Health International's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

160 Health International EBIT Chart

160 Health International Annual Data
Trend Dec22 Dec23 Dec24 Dec25
EBIT
-88.01 -108.62 -110.29 -78.54

160 Health International Semi-Annual Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial 0.00 -87.43 -23.58 -17.94 -60.41

HKSE:02656 vs MCK, COR, CAH: EBIT Comparison

For the Medical Distribution subindustry, 160 Health International's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

160 Health International EV-to-EBIT vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, 160 Health International's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where 160 Health International's EV-to-EBIT falls into.


HKSE:02656
8GF Score
160 Health International Ltd HKSE:02656
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

160 Health International EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-78.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of HK$-78.3 Mil mean?
160 Health International (HKSE:02656) has a EBIT of HK$-78.3 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on 160 Health International.
Is 160 Health International's EBIT too high?
160 Health International's current EBIT is HK$-78.3 Mil. Overall, 160 Health International has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does 160 Health International's EBIT compare to MCK and COR?
160 Health International's EBIT of HK$-78.3 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Distribution company?
A good EBIT depends on the Medical Distribution industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on 160 Health International. 160 Health International's current EBIT is HK$-78.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 160 Health International stock overvalued right now?
160 Health International (HKSE:02656) has a current EBIT of HK$-78.3 Mil. The current EBIT is HK$-78.3 Mil. 160 Health International's overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For 160 Health International (HKSE:02656), the current EBIT is HK$-78.3 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

160 Health International Business Description

Address 4078 Dongbin Road, Nanshan Street, 9th, 11th - 12th Floor, Building 2, Yongxin Times Square, Nanshan District, Shenzhen, CHN, 518052
160 Health International Ltd is an experienced pharmaceutical and healthcare product wholesaler and a digital healthcare integrated service provider in China. The company offers a wide assortment of high-quality pharmaceutical and healthcare products under both wholesale and retail models, to address a spectrum of customer needs. In addition, through its online healthcare and wellness service platform, Healthcare 160 Platform. It also provide digital healthcare and wellness solutions, empowering each Platform Participants, including business customers, medical and healthcare institutions, medical professionals, individual users, and third-party merchants, throughout the healthcare value chain and driving the digital transformation of China's healthcare and wellness industry.
8GF Score

Get the complete analysis for HKSE:02656

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$9.64
Price